ZUG, Switzerland, Nov. 2, 2016 /PRNewswire/ -- A recent study of nearly 100 surveyed US rheumatologists reveals that after approximately nine months on the market, not only are current users of Novartis' Cosentyx reporting increased PsA initiations, but the brand has also made significant gains in biologic patient share. Despite increased overall use of the IL-17 inhibitor, the percent of users has not changed since Q2, suggesting increased adoption by existing prescribers.
Though satisfaction among current Cosentyx users has also increased over the past quarter, with additional patient initiations comes more opportunity for discontinuation. Indeed, one-third of Cosentyx users report that they have had at least one patient discontinue use of the drug since initiation and Cosentyx discontinuations were most commonly attributed to a lack of efficacy or insurance coverage and cost issues.
Even though managed care/insurance and costs are considered major barriers for Cosentyx, future projections are positive, with rheumatologists anticipating significant growth in patient share over the next six months and 60% of non-users expecting to trial the drug in the same period.
Though many surveyed rheumatologists believe that Janssen's Stelara is the most at risk for displacement by Cosentyx, future projections show that gains in Cosentyx patient share will come at the expense of the established PsA TNF-inhibitors, namely AbbVie's Humira and Amgen's Enbrel. Though Janssen has enjoyed an increase in their PsA user-base, current use of Stelara has remained stable in the past quarter and is not expected to change in the next six months.
The Q4 wave of RealTime Dynamix™: Psoriatic Arthritis will further trend the launch of Cosentyx and include highlights from the annual ACR conference.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/despite-an-increase-in-psoriatic-arthritis-patients-initiated-on-cosentyx-over-the-past-three-months-the-user-base-for-novartis-il-17-inhibitor-has-remained-stable-300355473.html
SOURCE Spherix Global Insights